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Genetic Deficiency of Syk Protects
Mice From Autoantibody-Induced Arthritis
Zolta ´n Jakus, Edina Simon, Ba ´lint Bala ´zs, and Attila Mo ´csai
Objective. The Syk tyrosine kinase plays an im-
portant role in diverse functions in hematopoietic lin-
eage cells. Although previous in vitro and pharmaco-
logic analyses suggested Syk to be a possible player in
the development of autoimmune arthritis, no in vivo
genetic studies addressing that issue have yet been
reported. The aim of the present study was to test
whether genetic deficiency of Syk affects autoantibody-
induced experimental arthritis in the K/BxN serum–
transfer model.
Methods. Syk
/ bone marrow chimeras carrying
a Syk-deficient hematopoietic system were generated by
transplanting Syk
/ fetal liver cells into lethally irra-
diated wild-type recipients. After complete repopulation
of the hematopoietic compartment, autoantibody-
mediated arthritis was induced by injection of arthrito-
genic K/BxN serum. Arthritis development was moni-
tored by macroscopic and microscopic observation of
the ankle joints, micro–computed tomography of bone
morphology, as well as a joint function assay.
Results. Genetic deficiency of Syk in the hemato-
poietic compartment completely blocked the develop-
ment of all macroscopic and microscopic signs of ar-
thritis. The Syk
/ mutation also prevented the
appearance of periarticular bone erosions. Finally,
Syk
/ bone marrow chimeras were completely pro-
tected from arthritis-induced loss of articular function.
Conclusion. Our results indicate that Syk is crit-
ically involved in the development of all clinically rele-
vant aspects of autoantibody-mediated K/BxN serum–
transfer arthritis in experimental mice. These results
provide the first in vivo genetic evidence of the role of
Syk in the development of autoimmune arthritis.
Rheumatoid arthritis (RA) is a severe, chronic
autoimmune inflammatory disease affecting nearly 1%
of the human population (1). The requirement for better
and more cost-effective treatment strategies points to
the need for a deeper understanding of the disease
pathogenesis at the molecular level.
Autoimmune arthritis develops in 2 consecutive
phases in experimental animals, and based on indirect
(e.g., genetic) evidence, a similar scenario is expected to
apply to RA in humans. During the first (“initiation”)
phase, genetic and environmental factors lead to the
emergence of autoreactive T lymphocytes. During the
second (“effector”) phase, those autoreactive T cells
lead to synovial inflammation, proliferation, and bone
resorption through hematopoietic lineage cells and syno-
vial fibroblasts. The coupling between these 2 phases
likely involves autoantibody formation, as well as activa-
tion of cytokine networks (e.g., tumor necrosis factor
[TNF], interleukin-17 [IL-17]) (2). The reemerging
pathogenetic role of autoantibodies is supported by the
supposedly proarthritic nature of anti–cyclic citrulli-
nated peptide antibodies (3,4), the beneficial effect of B
cell depletion in human RA (5,6), and the capability of
autoantibodies to induce autoimmune arthritis in exper-
imental animals (7–9).
The K/BxN arthritis model is a widely used
transgenic mouse model of human RA. The peculiarity
of this model is that the disease can be transferred to
nonarthritic recipients by either the serum or the puri-
fied immunoglobulin fraction derived from arthritic
K/BxN mice (called K/BxN serum–transfer arthritis),
allowing the separate analysis of the autoantibody-
mediated effector phase of the disease. Indeed, K/BxN
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1899serum–transfer arthritis proceeds normally in RAG-
1
/ animals that lack both T and B lymphocytes (7).
Further analyses have revealed that K/BxN serum–
transfer arthritis is mediated by different myeloid lin-
eage cells (10–12) and the alternative pathway of com-
plement activation (13). This model also requires
immune complex recognition by Fc receptors (13,14),
as well as members of the 2 integrin family (15).
Syk is a nonreceptor tyrosine kinase involved in
diverse biologic functions, including immunoreceptor
(lymphocyte antigen receptor and Fc receptor) signaling
(16–20), certain integrin signal transduction processes
(21,22), osteoclast development and function (23,24),
vascular development (25), or innate immune recogni-
tion (26,27). While the functional role of Syk has been
extensively tested in a number of various in vitro cellular
assays, little is known about its role in live animals and in
vivo models of human diseases. This is likely due to the
perinatal lethality caused by Syk deficiency (16,17) pre-
cluding the analysis of adult Syk
/ animals.
Recently, R406, a small-molecule inhibitor, was
identified and shown to be a potent inhibitor of Syk and
of a number of supposedly Syk-dependent cellular re-
sponses of various lymphoid and myeloid lineage cells
(28). Importantly, R406 attenuated autoantibody-
induced arthritis in mice (28), whereas its orally bioavail-
able prodrug form R788, or fostamatinib, inhibited
collagen-induced arthritis in rats (29). Initial clinical
analysis of fostamatinib in RA also revealed significant
clinical benefit in patients receiving methotrexate ther-
apy (30), as well as in those whose RA previously failed
to respond to methotrexate therapy alone (www.rigel.
com/pdf/R788TASKI2-3RAResults.pdf). Those results
suggest that fostamatinib may be exploited as an oral
antirheumatic agent in the future.
While the in vivo effect of R406 (and its fosta-
matinib prodrug) on arthritis development is well docu-
mented, its selectivity for Syk is somewhat questionable.
The original conclusion that Syk is the primary target of
R406 was based on rather indirect evidence, and the
primary results of an in vitro kinase selectivity profiling
have not yet been published (28). While R406 exerted
half-maximal inhibition of Syk at 30 nM (28), it inhibited
the Flt-3 and Ret tyrosine kinases at 10 nM (31,32).
R406 also inhibited c-Kit, Lck, JAK-1/3, and the aden-
osine A3 receptor in the mid-nanomolar concentration
range (28). Most of those potential alternative R406
targets are involved in inflammation and autoimmunity
(33–37), providing a possible alternative explanation for
the beneficial effect of R406 on arthritis. Therefore, a
more specific (e.g., genetic) approach would be required
to unequivocally conclude that Syk is involved in arthritis
development.
Even if one assumes that R406 and fostamatinib
only act on Syk, a number of additional questions related
to the role of Syk in arthritis remain. First, those
inhibitors only partially decreased disease development
in animal models of autoimmune arthritis (28,29). It is,
at present, unclear whether the remaining disease activ-
ity was due to an incomplete inhibition of Syk or was due
to a parallel, Syk-independent mechanism. Second, it is
mostly unclear whether Syk participates in signaling
within hematopoietic or nonhematopoietic cells during
arthritis development. Indeed, while Syk is mostly ex-
pressed in the hematopoietic compartment, recent stud-
ies have suggested that it may also play a functional role
in synovial fibroblasts (38,39). Those issues could most
easily be addressed by analyzing the genetic deficiency of
Syk, preferably in an at least partially lineage-restricted
manner.
The above issues prompted us to test the role of
Syk in the pathogenesis of autoimmune arthritis by using
a genetic approach, that is, by testing the development of
the autoantibody-induced K/BxN serum–transfer arthri-
tis in chimeric mice with a Syk-deficient hematopoietic
compartment. Our results indicate that Syk present in
the hematopoietic compartment is indispensable for the
autoantibody-mediated component of autoimmune ar-
thritis.
MATERIALS AND METHODS
Animals. Heterozygous mice carrying a deleted Syk
allele (Syk
tm1Tyb, which is referred to as Syk
) (16) were
obtained from Victor Tybulewicz (National Institute for Med-
ical Research, London, UK). The mutation was maintained in
heterozygous (Syk
/) form on the C57BL/6 genetic back-
ground (i.e., carrying the CD45.2 allele). Mice carrying the
KRN T cell receptor (TCR) transgene (40) were obtained
from Diane Mathis and Christophe Benoist (Harvard Medical
School, Boston, MA) and were maintained in heterozygous
form by mating with C57BL/6 mice. KRN transgene–positive
mice were identified by flow cytometric analysis of the expres-
sion of the V6 TCR (40,41). NOD mice as well as a congenic
strain carrying the CD45.1 allele on the C57BL/6 genetic
background (B6.SJL-Ptprc
a) were purchased from The Jackson
Laboratory. Mice (4–6 per group) were maintained in individ-
ually sterile ventilated cages (Tecniplast) in a conventional
facility. All animal experiments were approved by the Semmel-
weis University Animal Experimentation Review Board.
Bone marrow transplantation. Bone marrow chimeras
with the Syk
/ hematopoietic system were generated by fetal
liver transplantation using fetuses from days 15.5–18.5 of
embryogenesis (E15.5–18.5), which were obtained from timed
matings of Syk
/ carriers. The 8–16-week-old recipient mice
carrying the CD45.1 allele on the C57BL/6 genetic background
were lethally irradiated as described (41) and then injected
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On average, fetal liver cells from a single donor were injected
into 5–8 recipients. Syk
/ fetuses were identified according to
their characteristic petechiated appearance (16,17) (Figure
1A), and their genotype was occasionally confirmed by allele-
specific polymerase chain reaction analysis (21). An equal
number of control chimeras were also generated using macro-
scopically normal (Syk
/ or Syk
/) sibling fetuses. Since our
initial experiments did not reveal any differences between
K/BxN serum–transfer arthritis in the Syk
/ and the Syk
/
mice (see below), no further distinction between those 2
genotypes was made, and we refer to both the Syk
/ and the
Syk
/ bone marrow chimeras as wild-type chimeras.
Assessment of chimerism. Peripheral blood samples
were taken 4–6 weeks after transplantation and stained with
phycoerythrin (PE)–labeled antibodies against CD45 (clone
30-F11, which recognizes all forms of CD45) or against Gr-1
(clone RB6-8C5), or were stained with biotin-conjugated anti-
bodies against CD11b (clone M1/70), the latter followed by
streptavidin–PerCP staining. Primary bone marrow–derived
macrophages were obtained as described previously (42) and
were stained with PE-labeled antibodies against the F4/80
antigen (clone CI:A3-1). All samples were counterstained with
fluorescein isothiocyanate–labeled antibodies against the
donor-specific CD45.2 epitope (clone 104). Except for the
anti-F4/80 antibody, which was purchased from AbD Serotec,
all antibodies were obtained from BD Biosciences. Flow
cytometry was performed using a FACSCalibur instrument,
and data were analyzed using CellQuest software (both from
BD Biosciences). The various leukocyte subsets were identified
based on their forward and side scatter characteristics and the
expression of the indicated lineage-specific markers, followed
by the assessment of the expression of the donor-specific
CD45.2 epitope.
For the analysis of Syk protein levels, total bone
marrow cells or bone marrow–derived macrophages were
immunoblotted using anti-Syk (N-19; Santa Cruz Biotechnol-
ogy) or anti–-actin (clone AC-74; Sigma) antibodies as de-
scribed elsewhere (42).
K/BxN serum–transfer arthritis. Mice carrying the
KRN TCR transgene (40) on the C57BL/6 background were
mated with NOD mice to obtain transgene-positive K/BxN
mice as well as their transgene-negative (BxN) littermates. The
presence of the KRN transgene was determined by flow
cytometric analysis of the expression of the V6 TCR in
circulating CD4 T cells as well as by looking for visible signs of
arthritis in the K/BxN mice, as described previously (40,41).
Blood was taken by retroorbital bleeding, and sera from KRN
transgene–positive and transgene–negative mice were pooled
separately.
Arthritis was induced by a single intraperitoneal injec-
tion of 400 l of arthritogenic (K/BxN) or control (BxN) serum
on day 0 of the experiment. Each experimental group con-
tained chimeras generated using 1–2 donor fetal livers. Chi-
meras generated using a total of 11 Syk
/ and an equal
number of wild-type control fetal livers were used during the
course of this study.
Assessment of arthritis. Arthritis severity in each
mouse was assessed daily for 2 weeks following serum injec-
tion. Visible signs of arthritis were scored on a scale of 0–10 by
2 investigators who were blinded as to the origin and treatment
of the mice (41). Ankle thickness was measured with spring-
loaded calipers (Kroeplin). Photographs were taken on day 8
of the disease.
To assess articular function, mice were placed on a
custom-made wire grid that was then flipped upside down, and
the length of time the mice held on to the wire grid during a
20-second assessment period was recorded (41). This test was
performed several times daily during the plateau phase of the
disease (days 8–12). The data obtained were combined into
“holding-on curves” similar to Kaplan-Meier survival curves.
Mice used in histologic analyses were killed on day 4,
their ankle joints were harvested, fixed in 10% formalin,
decalcified in OsteoMoll decalcifying solution (Merck Chem-
icals), embedded in paraffin, sectioned, and then stained with
hematoxylin and eosin. Photomicrographs were taken with a
Leica DMI 6000B inverted microscope.
Micro–computed tomography (micro-CT) analysis.
Mice used in the micro-CT analyses were killed on day 8, the
skin was removed, and the ankles were placed in phosphate
buffered saline containing 0.1% sodium azide. The ankles were
scanned using a SkyScan 1172 micro-CT apparatus operating
at a resolution of 9 m voxel size. Three-dimensional recon-
struction was performed using NRecon software, and the
images were further processed with CTanalyser software.
Once micro-CT analyses of the entire ankles were
completed, the tissues were digested overnight at 55°C in 0.2
mg/ml of proteinase K (Roche) in the presence of 1% sodium
dodecyl sulfate and 2 mM CaCl2. The first distal tarsal bones
were then identified and rescanned at a resolution of 5 m
voxel size.
Presentation of the data and statistical analysis. Re-
sults are expressed as the mean  SD of the indicated number
of individual data points. For the sake of clarity (i.e., to avoid
overlapping symbols and error bars), every second data point
was omitted from the presentation. For statistical analysis of
arthritis severity, average values obtained from the control
serum–treated animals of the same genotype in the same
experiment were subtracted from those of the arthritic serum–
treated animals. To avoid calculating with multiple values from
a single mouse, values for the left and right limbs in studies of
macroscopic arthritis were averaged, whereas data from a
single mouse in the joint function assays were combined into
individual holding-on curves before further analysis of statis-
tical significance. The data thus obtained were then compared
across the different genotypes by use of the nonparametric
Mann-Whitney U test using Statistica software (StatSoft).
Arthritis severity was analyzed on day 9. Joint function was
assessed at the 20-second time point. Exact P values less than
0.05 were considered to be statistically significant.
RESULTS
Generation of Syk
/ bone marrow chimeras and
assessment of chimerism. Complete genetic deficiency
of Syk leads to a petechiated in utero appearance
(Figure 1A) and perinatal lethality (16,17), which are
likely due to a lymphatic vascular developmental defect
(25). This problem was overcome by the generation of
bone marrow chimeras with a Syk
/ hematopoietic
system in an otherwise normal nonhematopoietic envi-
ronment (21). To this end, Syk
/ fetal liver cells were
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mice (Figure 1B). An equal number of Syk-sufficient
(Syk
/ or Syk
/) control chimeras were also gener-
ated; these are referred to herein as wild-type chimeras.
Recipients were chosen to carry the CD45.1 allele,
which can be distinguished from the donor-derived
CD45.2 allele by patterns on flow cytometry. The gen-
erated Syk
/ bone marrow chimeras did not show any
overt phenotype during the course of this study (usually,
4–10 weeks after transplantation).
To confirm the complete replacement of the
hematopoietic compartment, we tested the presence of
donor-specific markers in bone marrow chimeras. As
shown in Figure 1C, circulating leukocytes (i.e., cells
expressing the pan-leukocyte marker CD45) of both
wild-type and Syk
/ chimeras were nearly exclusively of
donor origin (CD45.2). Since K/BxN serum–transfer
arthritis requires various myeloid cell types (10,11), we
also analyzed various myeloid lineages. As shown in
Figure 1C, circulating neutrophils (defined as Gr-1
cells) and monocytes (CD11bGr-1– cells) from peri-
pheral blood samples, as well as bone marrow–derived
macrophages (F4/80 cells) of both wild-type and
Syk
/ chimeras were all exclusively of donor origin
(CD45.2). Additional experiments in which Syk pro-
tein expression was analyzed by immunoblotting re-
vealed that Syk was absent from lysates of total bone
marrow cells or bone marrow–derived macrophages
from Syk
/ chimeras, but not from parallel generated
wild-type control chimeras (Figure 1D).
Figure 1. Generation and analysis of Syk
/ bone marrow chimeric mice. A, Macroscopic appearance of wild-type (WT) and Syk
/ mouse fetuses
at 17.5 days postcoitum (embryogenesis day 17.5). B, General scheme of fetal liver transplantation procedure. C, Flow cytometric analysis of donor
marker (CD45.2) expression in all circulating leukocytes (CD45 gate), circulating neutrophils (Gr-1 gate), circulating monocytes (CD11bGr-1–
gate), and bone marrow (BM)–derived macrophages (F4/80 gate) from intact (nonchimeric) mice of the CD45.1-expressing recipient strain or the
CD45.2-expressing donor (C57BL/6) strain, as well as from wild-type or Syk
/ bone marrow chimeras. D, Immunoblot analysis of Syk and -actin
protein levels in total bone marrow cells or bone marrow–derived macrophages. Results are representative of 3 or more independent experiments,
each of which showed similar results. Actin was used as a loading control.
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proach allowed us to generate bone marrow chimeras
with a Syk
/ hematopoietic compartment.
Protection of Syk
/ chimeras from clinical signs
of autoantibody-induced arthritis. To test the contribu-
tion of Syk to K/BxN serum–transfer arthritis, wild-type
and Syk
/ chimeras were injected with arthritogenic
(K/BxN) serum or control serum. While arthritogenic
serum triggered severe inflammation of the hind paws of
wild-type bone marrow chimeras, no signs of the disease
were seen in similarly treated Syk
/ chimeras (Figure
2A). Quantification of hind paw arthritis by clinical
Figure 2. Assessment of the macroscopic signs of arthritis in Syk
/ bone marrow chimeric mice. A, Photographs of the hind limb of wild-type (WT)
or Syk
/ chimeras 8 days after a single injection of 400 l of arthritogenic (K/BxN) or control (BxN) serum. B–D, Quantification of arthritis severity
by hind limb (B) or fore limb (C) clinical scoring or by measurement of ankle thickness (D). Experiments were performed on all 4 limbs of 6 control
serum– and 11 arthritogenic serum–treated mice per genotype in 4 independent experiments. Shown are representative photographs (A) or the mean
and SD values (B–D) of 2 limbs per mouse from all mice tested.
Figure 3. Normal arthritis development in heterozygous Syk
/ mice. Arthritis severity was quantified by hind limb (A) or fore limb (B) clinical
scoring or by measurement of ankle thickness (C) in intact (nonchimeric) homozygous Syk
/ or heterozygous Syk
/ mice after a single injection
of 400 l of arthritogenic (K/BxN) or control (BxN) serum. Experiments were performed on all 4 limbs of 5 control serum– and 10 arthritogenic
serum–treated mice per genotype in 3 independent experiments. Values are the mean and SD of 2 limbs per mouse from all tested mice combined.
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marrow chimeras injected with arthritogenic K/BxN
serum, whereas no disease was seen in similarly treated
Syk
/ chimeras (Figure 2B). Compared with the clini-
cal scores in control serum–injected mice, injection of
arthritogenic serum caused a marked increase (mean 
SD 7.5  2.2 points) in the clinical score in wild-type
chimeras on day 9, whereas the same treatment caused a
negligible decrease (0.02  0.2 points) in Syk
/ chime-
ras. The difference between the 2 genotypes was highly
statistically significant (P  1.5  10
6;n 11). A
complete lack of arthritis development was also ob-
served in the fore limbs of Syk
/ chimeras (Figure 2C).
Ankle thickness measurements also indicated a
robust thickening of the ankles of arthritogenic serum–
injected wild-type bone marrow chimeras, whereas no
increase was seen in similarly treated Syk
/chimeras
(Figure 2D). Quantitative analyses indicated that injec-
tion of arthritogenic serum increased the ankle thickness
in wild-type chimeras by a mean  SD of 1.1  0.3 mm
over that in control serum–treated animals on day 9,
whereas the same treatment led to a negligible increase
of 0.01  0.1 mm in Syk
/ chimeras. The difference
between the 2 genotypes was again highly significant
(P  1.5  10
6;n 11).
Taken together, the data indicate that hemato-
poietic expression of Syk is indispensable for the devel-
opment of clinical signs of arthritis in the K/BxN serum–
transfer model.
Normal course of K/BxN serum–transfer arthri-
tis in heterozygous Syk
/ animals. The preceding
experiments tested the effect of the complete deletion of
Syk in the hematopoietic compartment. We next inves-
tigated whether the partial reduction of Syk expression
Figure 4. Histologic analysis of the ankle joints of Syk
/ bone marrow chimeric mice. Photomicrographs of hematoxylin and eosin–stained sagittal
sections of the ankle joints of wild-type (WT) or Syk
/ chimeras 4 days after a single injection of 400 l of arthritogenic (K/BxN) or control (BxN)
serum are shown. In each case, sections obtained at 50 magnification show the joint formed between the tibia (above) and the astragalus (below)
bones (the latter corresponding to the human talus), with the posterior surface pointing to the left. Boxed areas in images shown at 50
magnification are shown at 100 magnification in images in the center column, and boxed areas in images shown at 100 magnification are shown
at 200 magnification in images in the right column. Bars  500 m, 200 m, and 100 m for 50, 100, and 200 magnification, respectively.
Images are representative of a large number of sections obtained from 3 independent experiments, each of which showed similar results.
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tis. To this end, we compared the severity of K/BxN
serum–transfer arthritis in intact (nonchimeric) Syk
/
and Syk
/ littermates. Clinical scores in the hind limbs
(Figure 3A) did not reveal any significant differences in
disease severity between the 2 genotypes (clinical score
on day 9 increased by a mean  SD of 7.7  1.4 and
6.8  1.9 in Syk
/ and Syk
/ mice, respectively [P 
0.24]; n  10), nor were any considerable differences
in clinical scores in the fore limbs seen between the 2
genotypes (Figure 3B). Similarly, the Syk
/ mutation
did not significantly affect ankle thickening (ankle thick-
ness on day 9 increased by 1.3  0.3 and 1.0  0.3 mm
in Syk
/ and Syk
/ mice, respectively [P  0.11]; n 
10) (Figure 3C). Those results indicate that approxi-
mately half of the Syk kinase activity is sufficient to
support mostly normal development of autoantibody-
induced arthritis.
Histologic analysis of arthritis in Syk
/ bone
marrow chimeras. Next, we performed histologic analy-
sis of arthritis development in the chimeras. Hematoxy-
lin and eosin–stained sections of the joints obtained 4
days after serum injection showed that between the tibia
and astragalus bones (the latter corresponding to the
talus in humans), arthritogenic serum induced a robust
leukocytic infiltration of the periarticular tissues in
wild-type chimeras (Figure 4). This infiltrate even
eroded the marginal areas of the articular surface and
invaded the juxtaarticular free (non–joint-forming) bone
surface of the tibia. Importantly, no leukocytic infiltra-
tion or erosion was seen in Syk
/ bone marrow chime-
ras that had been injected with arthritogenic serum
Figure 5. Micro–computed tomography (micro-CT) of the ankle joints of Syk
/ bone marrow chimeric mice. A and B, Three-dimensional
reconstruction of the ankle bones of wild-type (WT) and Syk
/ bone marrow chimeras obtained by micro-CT at 9 m voxel size on day 8 after a
single injection of 400 l of arthritogenic (K/BxN) or control (BxN) serum. Boxed areas in A are shown at higher digital magnification in B. Arrow
in B indicates the first distal tarsal bone. C, Three-dimensional images of the first distal tarsal bone obtained by micro-CT at 5 m voxel size after
complete digestion of the ankle joints. Images are representative of 3 ankles per group obtained from 3 independent experiments, each of which
showed similar results.
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ment is required for the development of microscopic
signs of arthritis, such as leukocyte accumulation or
periarticular erosion of the bone and cartilage surface.
Lack of periarticular bone erosions in Syk
/
bone marrow chimeras. Arthritis-induced periarticular
bone erosions lead to irreversible loss of the joint
architecture and indicate a poor prognosis of the dis-
ease. Arthritis-induced bone erosions result from the
activity of osteoclasts (43–46), which have previously
been shown to rely on Syk for their development and
function (23,24). To obtain a detailed picture of the
erosion of mineralized bone tissue, we performed
micro-CT analysis of the ankle area of our bone marrow
chimeras. As shown in Figures 5A and B, injection of
arthritogenic serum induced marked erosions of the
periarticular bone surfaces in wild-type chimeras, even
punching holes across several tarsal bones. In contrast,
the periarticular bone surfaces of similarly treated
Syk
/ chimeras were smooth and unaffected, similar
to those of control serum–treated animals (Figures 5A
and B).
A more-detailed analysis of the first distal tarsal
bone (equivalent of the first cuneiform bone in humans)
(white arrows in Figure 5B) after proteolytic digestion of
the ankle showed extensive surface erosions and several
holes across the entire bone in arthritogenic serum–
injected wild-type chimeras (Figure 5C). In contrast, the
architecture and bone surface of the first distal tarsal
bone of similarly treated Syk
/ chimeras did not show
any signs of bone erosion.
Taken together, these findings indicate that Syk
in the hematopoietic compartment is required for the
development of periarticular bone erosions during
autoantibody-induced arthritis.
Protection of Syk
/ bone marrow chimeras
from arthritis-induced loss of articular function. Be-
sides macroscopic and microscopic signs of inflamma-
tion, arthritis also leads to severe impairment of articular
function. This was assessed by testing the ability of our
chimeras to hold on to the bottom of a horizontal wire
grid (41). As shown in the video snapshots in Figure 6A,
control serum–treated chimeras held on to the grid for
the entire 20-second period, whereas wild-type chimeras
injected with arthritogenic serum fell off the grid within
a few seconds, indicating an arthritis-induced loss of
articular function. Importantly, Syk
/ bone marrow
chimeras injected with arthritogenic serum were able to
Figure 6. Protection of Syk
/ bone marrow chimeric mice from arthritis-induced loss of articular function. Wild-type (WT) or Syk
/ bone marrow
chimeras were injected with a single dose of 400 l of arthritogenic (K/BxN) or control (BxN) serum. On days 8–12 after serum injection, the mice
were placed on a custom-made wire grid, which was then flipped over, and the length of time the mice held on to the wire grid during a 20-second
assessment period was recorded. A, Snapshots from the video captures of mice of the indicated genotype and treatment groups 10 days after serum
injection. B, Percentages of mice that were able to hold on to the grid at the indicated time points after the grid was flipped over. The experiment
was repeated 15–20 times per mouse (n  6 control serum–treated and n  11 arthritic serum–treated chimeras per genotype in 4 independent
experiments). Shown are representative snapshots (A) or the mean and SD values (B) for each group of mice tested.
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assessment (Figure 6A).
The above experiment was repeated several times
on each mouse 8–12 days after serum injection, and the
percentages of mice that were able to hold on to the grid
for a given period were calculated analogous to the
calculation of Kaplan-Meier survival curves. While more
than 90% of control serum–treated chimeras held on to
the wire grid for the entire 20-second assessment period,
only 10% of the wild-type chimeras injected with
arthritogenic serum were able to do so (Figure 6B).
Importantly, arthritogenic serum–treated Syk
/ chime-
ras held on to the wire grid as well as the control
serum–injected animals had (Figure 6B). Statistical ana-
lysis revealed that, compared with control serum–treated
animals, treatment with arthritogenic serum caused an
additional 85  16% and 3.4  7.6% (mean  SD) of
the wild-type and Syk
/ chimeras, respectively, to fall
off the grid during the 20-second assessment period (P 
1.5  10
6;n 11).
Taken together, the findings show that genetic
deficiency of Syk in the hematopoietic compartment
protects mice from arthritis-induced loss of articular
function.
DISCUSSION
Development of better, safer, and cheaper ther-
apeutic strategies for RA would require better under-
standing of the pathologic mechanism of the disease at
the molecular level. While previous pharmacologic stud-
ies have suggested a role for the Syk tyrosine kinase in
the development of autoimmune arthritis, all of those
studies were based on a single pharmacologic agent with
limited specificity for Syk. Using mice that are geneti-
cally deficient in Syk, our experiments showed that Syk
within the hematopoietic compartment is required for
autoantibody-induced arthritis to occur in the K/BxN
serum–transfer model. These studies provide the first
genetic evidence of the role of Syk in the pathogenesis of
autoimmune arthritis.
During the last decade, tyrosine kinase inhibitors
have been demonstrated to have major therapeutic
potential in diverse diseases, particularly tyrosine
kinase–dependent tumors. While most of those drugs
were originally considered to be specific for a particular
kinase, later studies revealed that they also affect other
tyrosine phosphorylation pathways. Imatinib, for exam-
ple, was originally developed to inhibit the breakpoint
cluster region (BCR)-Abl fusion protein, but it was later
shown to also inhibit c-Kit and the platelet-derived
growth factor receptor. Similarly, dasatinib inhibits
BCR-Abl fusion protein and Src family kinases, but it
also affects other kinases, such as c-Kit or the ephrins.
Indeed, it has proved rather difficult to specifically
target a given kinase, especially because most of these
drugs act as competitive inhibitors at the highly con-
served ATP-binding pocket. However, despite their lim-
ited specificity, these drugs clearly provide major clinical
benefit in various groups of patients, indicating that
specificity for a single kinase is not necessarily a prereq-
uisite for the clinical usefulness of a tyrosine kinase
inhibitor. Indeed, a particular spectrum of different
targets (“multiple targeting”) may actually be more
beneficial in a given clinical setting.
Fostamatinib (R788), an orally bioavailable pro-
drug of the R406 tyrosine kinase inhibitor, has been
developed for the treatment of allergic and inflamma-
tory diseases, and it has recently been found to provide
significant therapeutic benefit in certain RA patients as
well (see ref. 30 and www.rigel.com/pdf/R788TASKI2-
3RAResults.pdf). R406 has been shown to be a potent
inhibitor of Syk, acting as a competitive inhibitor at the
ATP-binding site (28). However, additional studies re-
vealed that it also affects other targets, including the
Flt-3, Ret, c-Kit, Lck, and JAK-1/3 tyrosine kinases, the
adenosine A3 receptor, as well as several additional
kinases and nonkinase targets, often at concentrations
comparable to, or even lower than, those inhibiting Syk
(28,31,32). The role of most of those potential R406
targets in inflammation and autoimmunity (33–37) could
even provide an alternative explanation for the effect of
R406 in arthritis development. Taken together, R406/
fostamatinib should not be considered a specific inhibi-
tor of Syk tyrosine kinase, and the beneficial effect of
R406 or fostamatinib on autoimmune arthritides should
not be considered formal proof of the role of Syk in the
pathogenesis of those diseases.
By using an approach that is independent of, and
conceptually different from, the above pharmacologic
approach, our genetic studies presented herein provide
independent evidence of the role of Syk in the
autoantibody-mediated component of the effector phase
of autoimmune arthritis. Together with the findings of
the above pharmacologic studies, we can now confi-
dently conclude that Syk is indeed an important compo-
nent of at least certain aspects of the pathogenesis of
autoimmune arthritis.
Besides providing the first genetic evidence for
the role of Syk in arthritis, our results also allow a more
detailed understanding of how Syk participates in arthri-
tis development. Previous studies showing a partial
reduction of arthritis severity by treatment with R406 or
fostamatinib in animal models of arthritis, including the
GENETIC STUDIES ON Syk IN AUTOIMMUNE ARTHRITIS 1907K/BxN serum–transfer arthritis model (28,29), raised the
possibility that the lack of Syk activity can be partially
compensated for by another, Syk-independent mecha-
nism. Our results showing complete protection of
Syk
/ bone marrow chimeras from arthritis develop-
ment in the K/BxN serum–transfer model indicate that,
at least in the case of autoantibody-induced arthritis, no
Syk-independent component exists. Previous pharmaco-
logic studies could not address whether the presence of
Syk is required in hematopoietic or nonhematopoietic
cells to support arthritis development. Indeed, while the
primarily hematopoietic expression of Syk supported the
former scenario, recent studies have also suggested a
role of Syk in synovial fibroblasts of RA patients (38,39).
Our results obtained in studies of chimeric mice lacking
Syk only in the hematopoietic compartment indicate
that Syk within the hematopoietic compartment is indis-
pensable for the autoantibody-mediated component of
autoimmune arthritis (though it does not exclude the
possibility of a parallel role of Syk in synovial fibro-
blasts).
RA is a complex disease with various consecutive
phases and several parallel signaling mechanisms. While
our studies identified Syk as a critical player in the
autoantibody-induced component of autoimmune ar-
thritis, no conclusion about the role of Syk in other
components of the disease, such as autoantibody forma-
tion or cytokine (TNF, IL-17, etc.)–mediated activation
of effector cells, should be drawn (2). Instead, these
questions need to be addressed by other appropriate
approaches, such as analysis of Syk
/ bone marrow
chimeras, in additional experimental models of arthritis.
It has been proposed that K/BxN serum–transfer
arthritis is mediated by a number of nonlymphoid lin-
eages of hematopoietic origin. Given the critical role of
neutrophils in K/BxN serum–transfer arthritis (10) and
the requirement for Syk in integrin (21) and Fc receptor
(18) signaling in neutrophils, we expect that Syk in
neutrophils makes a major contribution to the observa-
tions described herein. We are less certain about the
functional role of Syk in other hematopoietic lineages.
While macrophages also rely on Syk for signaling by
integrins (47) and Fc receptors (18,48), their contribu-
tion to arthritis development in the K/BxN serum–
transfer model is a subject of some controversy (com-
pare ref. 11 with ref. 49). There are controversies related
to the role of mast cells in experimental arthritis as well
(compare refs. 12 and 50 with ref. 51), and our bone
marrow transplantation approach is unlikely to replace
all tissue mast cells, given the inherent radioresistance of
that cell lineage (52). While we and other investigators
have shown that Syk is required for osteoclast develop-
ment and function (23,24), we cannot exclude the pos-
sibility that the lack of bone erosions in Syk
/ bone
marrow chimeras is secondary to the defective process of
inflammation, rather than being due to a cell-
autonomous defect of Syk
/ osteoclasts in the resorp-
tion of bone in an inflammatory environment. Finally, as
mentioned above, our experimental approach cannot
provide any information on the role of Syk within cells of
nonhematopoietic origin. Obviously, further lineage-
specific studies will be needed in order to identify the
lineage(s) requiring Syk for signaling during the devel-
opment of autoimmune arthritis.
Although initial studies of Syk suggested that it is
primarily involved in signaling by classic immunorecep-
tors (20), later studies also indicated its role in signaling
by integrins (21,53) and C-type lectins (27,54), as well as
in the activation of the NLRP3 inflammasome (26). Of
those pathways, Fc receptors (13,14) and 2 integrins
(15) are well known for their role in the K/BxN serum–
transfer arthritis, and various forms of arthritis have
also been associated with C-type lectins (55) and the
NLRP3 inflammasome (56,57). Hence, there are a num-
ber of possible intracellular signaling pathways that may
rely on Syk to promote the development of autoimmune
arthritis.
An interesting observation of our study was the
complete absence of joint-infiltrating leukocytes in
Syk
/ bone marrow chimeras. While the role of Syk in
integrin signaling would suggest a cell-autonomous de-
fect of 2 integrin–mediated leukocyte migration (com-
pare ref. 21 with ref. 12), results of previous observations
of the normal accumulation of Syk
/ neutrophils in
vivo (21,58) are evidence against that possibility. A more
likely scenario is that the genetic deficiency of Syk
prevents the development of a proper inflammatory
environment, leading to the failure of leukocyte migra-
tion because of the lack of a migration-promoting cyto-
kine and chemokine milieu, rather than because of a
cell-autonomous migration defect.
Taken together, our results provide the first in
vivo genetic evidence of the role of Syk in the develop-
ment of autoimmune arthritis in mice and provide
important insight into how Syk participates in the dis-
ease. However, further detailed experiments will be
required to elucidate other aspects of the role of Syk in
arthritis development that could not be addressed in this
project.
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